Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of VTE…
Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of VTE…
Clarivate Epidemiology’s coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of…
Clarivate’s Epidemiology’s coverage of RP comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany,…
Clarivate Epidemiology’s coverage of diabetic nephropathy (DN) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report…
Clarivate Epidemiology’s coverage of diabetic nephropathy (DN) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report…
Clarivate Epidemiology’s coverage of spinal muscular atrophy (SMA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Diabetic macular edema (DME) associated with diabetic retinopathy (DR) is a rapidly evolving market as a result of multiple intravitreal (IVT) pharmacotherapy approvals across different drug…
Clarivate Epidemiology’s coverage of atrial fibrillation (AF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AF for each…
Clarivate Epidemiology’s coverage of genitourinary syndrome of menopause (GSM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…
Since 2018, seven novel drugs have entered the U.S. market for the acute or preventive treatment of migraine, and at least four more are on the short-term horizon. Understanding how prescribers…
Clarivate Epidemiology has created a robust repository of the prevalence of biomarker- and mutation-defined treatment-eligible cancer populations. Using Clarivate’s Biomarker Epidemiology, you…